Natural killer T cells in cancer immunotherapy
S Nair, MV Dhodapkar - Frontiers in immunology, 2017 - frontiersin.org
Natural killer T (NKT) cells are specialized CD1d-restricted T cells that recognize lipid
antigens. Following stimulation, NKT cells lead to downstream activation of both innate and …
antigens. Following stimulation, NKT cells lead to downstream activation of both innate and …
The current landscape of NKT cell immunotherapy and the hills ahead
Simple Summary Natural killer T (NKT) cells are a subset of lipid-reactive T cells that
enhance anti-tumor immunity. While preclinical studies have shown NKT cell …
enhance anti-tumor immunity. While preclinical studies have shown NKT cell …
[HTML][HTML] Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting
Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical
remissions in CD19+ B cell lymphomas are often short lived. We tested whether CAR19 …
remissions in CD19+ B cell lymphomas are often short lived. We tested whether CAR19 …
Invariant natural killer T cells in immune regulation of blood cancers: harnessing their potential in immunotherapies
Invariant natural killer T (iNKT) cells are a unique innate T lymphocyte population that
possess cytolytic properties and profound immunoregulatory activities. iNKT cells play an …
possess cytolytic properties and profound immunoregulatory activities. iNKT cells play an …
[PDF][PDF] Single-cell transcriptomic landscape of nucleated cells in umbilical cord blood
Background For both pediatric and adult patients, umbilical cord blood (UCB) transplant is a
therapeutic option for a variety of hematologic diseases, such as blood cancers …
therapeutic option for a variety of hematologic diseases, such as blood cancers …
Invariant NKT cells increase drug‐induced osteosarcoma cell death
S Fallarini, T Paoletti, N Orsi Battaglini… - British journal of …, 2012 - Wiley Online Library
BACKGROUND AND PURPOSE In osteosarcoma (OS) patients, only a limited number of
drugs are active and the regimens currently in use include a combination of at least two of …
drugs are active and the regimens currently in use include a combination of at least two of …
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
S Corgnac, R Perret, L Derré, L Zhang… - Cancer Immunology …, 2013 - Springer
Despite the well-established antitumor activity of CD1d-restricted invariant natural killer T
lymphocytes (iNKT), their use for cancer therapy has remained challenging. This appears to …
lymphocytes (iNKT), their use for cancer therapy has remained challenging. This appears to …
CD1b-autoreactive T cells recognize phospholipid antigens and contribute to antitumor immunity against a CD1b+ T cell lymphoma
S Bagchi, S Li, CR Wang - Oncoimmunology, 2016 - Taylor & Francis
Adoptive immunotherapy for cancer treatment is an emerging field of study. Till now, several
tumor-derived, peptide-specific T cell responses have been harnessed for treating cancers …
tumor-derived, peptide-specific T cell responses have been harnessed for treating cancers …
The role of natural killer T cells in B cell malignancies
G Ghalamfarsa, A Hadinia, M Yousefi, F Jadidi-Niaragh - Tumor Biology, 2013 - Springer
Little is known regarding the precise role of different subsets of natural killer T (NKT) cells in
the immunopathogenesis of cancer diseases, particularly hematopoietic malignancies …
the immunopathogenesis of cancer diseases, particularly hematopoietic malignancies …
CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy
J Huang, Q Yang, W Wang, J Huang - Frontiers in Immunology, 2024 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has transformed cancer immunotherapy.
However, significant challenges limit its application beyond B cell-driven malignancies …
However, significant challenges limit its application beyond B cell-driven malignancies …